Associate Director, Precision Medicine

Could you provide the scientific leadership in Precision Medicine that enables a world-leading biopharmaceutical company to change the way healthcare is delivered to individual patients?

At AstraZeneca, we're looking for Precision Medicine Leads to join our Precision Medicine and Biosamples department.

Join a place built on innovation and creativity, where different views and perspectives are encouraged and valued. An environment that nurtures inclusion, and teams that reflect the diversity of the communities that we serve.

We're passionate about providing medicines that make a real difference to patient care, and precision medicine is at the heart of our dedication to patient centric science and innovation.

Using innovative diagnostic tests to evaluate individual responses to treatments, we strive to select appropriate and optimal therapies for patients who will benefit from them most. We apply precision medicine approaches across all therapy areas (TAs), and in over 85% of drug projects in our pipeline, which sets us apart from our competitors.

In Gothenburg, Sweden or Cambridge (Melbourn Science Park), UK , you'll be working alongside some of the brightest scientific talents in a vibrant, creative environment. With outstanding facilities, you'll find yourself being able to immerse yourself in your work, advance your career and contribute towards scientific excellence. It's a place that inspires innovation and where research-led ideas are turned into new medicines that make a real difference in healthcare.

As well as thriving in our multidisciplinary setting, you will able to work collaboratively with external diagnostic companies and outstanding research institutes.

What you'll do
As a member of the Biopharmaceutical Precision Medicine Unit you will drive precision medicine across a wide range of chronic disease areas.

Your objective will be to ensure that complementary & companion diagnostic tests, or equivalent patient segmentation tools, are delivered to drug projects.

This will entail implementing the strategy agreed with early and late stage project teams and leading activities comprising scientific & technical aspects of test development, test deployment into clinical trials, enabling regulatory & intellectual property strategies and financial tracking.

Providing advice on strategy, approaches and diagnostic development to product teams, you will be fundamental in ensuring that we adopt outstanding ordinary practice in the field to increase the likelihood of successful drug launch and return on investment. You will explore and bring in new technologies to push the boundaries of diagnostics in chronic disease and help to establish AstraZeneca as the world leading Precision Medicine Company.


Essential for the role

*

Degree level or equivalent experience in a similar subject
*

Experience in the development of complementary and companion diagnostic tests, or patient segmentation tools, and their implementation in clinical studies
*

Evidence of delivery and experience of precision medicine approaches & diagnostic development
*

Knowledge of the regulatory environment for companion/complimentary diagnostics
*

An understanding of any relevant chronic disease area
*

Excellent skills in communication, influencing, programme management
*

Significant understanding of the functions involved in diagnostic development


Desirable for the role

*

Experience of developing diagnostic tests, regulatory interactions and test commercialisation
*

Record of publications and a positive reputation in the precision medicine field


This is an exciting opportunity for a Precision Medicine expert to join an excellent team at the forefront of precision medicine science, to innovate and support the portfolio of a company that has science at its heart and a growing pipeline whilst being based in the appealing city of Gothenburg, Sweden or Cambridge, UK.

So, what's next?
Are you already envisioning yourself joining our team? Good, because we can't wait to hear from you! Please apply no later than November 20th, 2022.